At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 459 enrolled
Drug / intervention
Galcanezumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients With Episodic Migraine
In Brief
A Phase 2 clinical trial evaluating Galcanezumab and Placebo for Migraine. Completed, enrolled 459 participants across 47 sites.
Detailed Summary
The main purpose of this study is to determine the efficacy of the study drug Galcanezumab in Japanese participants with episodic migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartNov 2016
Primary CompletionJan 2019
TodayJul 2026
First PostedNov 8, 2016
Enrollment StartNov 9, 2016
Primary CompletionJan 18, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 9.7 years ago
Interventions
Galcanezumabdrug
Administered SC
Placebodrug
Administered SC